Global Uterine Fibroid Diagnostics and Therapeutics Market- Forecast and Analysis (2020-2027): by Type, by Diagnosis, by Treatment, and by Region.


Global Uterine Fibroid Diagnostics and Therapeutics Market is expected to reach US$ 832 Mn. at a CAGR of 10.6 during the forecast period 2027.

 

Global Uterine Fibroid Diagnostics and Therapeutics Market

To know about the Research Methodology :- Request Free Sample Report

The report covers an in-depth analysis of COVID 19 pandemic impact on Global Uterine Fibroid Diagnostics and Therapeutics Market by region and on the key players’ revenue affected till July 2020 and expected short term and long-term impact on the market.

Global Uterine Fibroid Diagnostics and Therapeutics Market overview

Uterine fibroid is a tumor that develops in the muscular wall of the uterus. It arises from the smooth muscle tissues of the uterus. This non-cancerous tumor is also known as, fibroleiomyoma, leiomyoma (benign tumor), myoma, and fibromyoma. They vary from size-to-size from tiny to larger. Fibroids are the common form especially during pregnancy periods of the woman. A fibroid tumor that is uncountable is known as uterine leiomyomatosis. The uterine fibroids, often during 5 months of pregnancy, help the uterus develop. If it is malignant also known as leiomyosarcoma is very uncommon. It causes extreme bleeding swelling of the abdomen, lower back pain, and mental structural cramping. Increasing the cure for these diseases has fuelled the growth of the market. Ultrasound instruments, due to their usefulness and popularity for gynaecological purposes, are commonly used to diagnose uterine fibroids. It also emits no harmful rays that can affect the foetus (if women are pregnant with uterine fibroids), raising its choice among radiologists.

Global Uterine Fibroid Diagnostics and Therapeutics Market Dynamics

The growth of this market has been motivated by rise in prevalence due to inheritance and growing number of therapies to cure this disease. Besides, the global Uterine Fibroid Diagnostics and Therapeutics market is expected to grow owing to increasing health care expenditure and increasing fibroids drugs market over the forecast period. The change in lifestyle, changing in food habits, and hectic lifestyle increases the demand for healthcare products and dietary supplements. The demand to cure such diseases has led the manufacturers to take keen interest in Uterine Fibroid Diagnostics and Therapeutics market.

However, increasing high costs of these machines with the adoptions of robots in surgeries are expected to restrain the market. Besides, government stringent regulations may hamper the market for the Uterine Fibroid Diagnostics and Therapeutics market.
The woman pregnancy and consumer awareness about various diagnosed technique such as, computed tomography (CT) scanners, medical resonance imaging (MRI) scanners and ultrasound devices have boosted the demand for Uterine Fibroid Diagnostics and Therapeutics market. Various physician has adopted these artificial intelligence robotic techniques owing to the positive responses and better results on the uterine fibroid.

Global Uterine Fibroid Diagnostics and Therapeutics Market: Market Segmentation

Global Uterine Fibroid Diagnostics and Therapeutics Market is Segmented by Type Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and others), by Diagnosis (Medical Resonance Imaging (MRI) scanners, Computed Tomography (CT), Ultrasounds and others), by Treatment (Uterine Fibroid Embolization, Magnetic Resonance Guided Focused Ultrasound, Myolysis, Endometrial Ablation, Hysterectomy and Myomectomy), and by Region (North America, Europe, Asia-Pacific, South America and Middle East & Africa).

Global Uterine Fibroid Diagnostics and Therapeutics Market: Regional Analysis

The regional analysis of the worldwide uterine fibroid diagnostics and therapeutics market is segregated across North America, Europe, Asia Pacific, the Middle East and Africa, and South America. The worldwide demand for Uterine Fibroid Diagnostics and Therapeutics is expected to record the greatest growth in the Asia Pacific region. Increasing number of women of reproductive age (WRA) has positive impact on the Uterine Fibroid Diagnostics and Therapeutics market. Increasing investment and consumer changing lifestyle is expected to increase the demand for fibroid diagnostics market. Besides, approximately 75 million WRAs were registered in 2014, according to the Centers for Disease Control and Prevention (CDC), and this number is projected to increase with the growing number of women worldwide. According to the World Data Book, in 2011 , the total population of women was about 3,439.4 million and this number is projected to increase predominantly in developing countries such as India and China due to improved education systems has positive impact on the Uterine Fibroid Diagnostics and Therapeutics market.

Report covers in-depth analysis of key development, marketing strategies, supply-side and demand side indicators and company profiles of market leaders, potential players, and new entrants. Key players operating in this market are adopting various organic and inorganic growth strategies such as merger& acquisitions, joint ventures, collaborations, expansion, new product launches and patents to increase their regional presence and business operations.

The objective of the report is to present a comprehensive analysis of the Global Uterine Fibroid Diagnostics and Therapeutics Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that includes market leaders, followers, and new entrants. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors of the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analysed, which will give a clear futuristic view of the industry to the decision-makers. The report also helps in understanding Global Uterine Fibroid Diagnostics and Therapeutics Market dynamics, structure by analyzing the market segments and project Global Uterine Fibroid Diagnostics and Therapeutics Market Clear representation of competitive analysis of key players by price, financial position, Product portfolio, growth strategies, and regional presence in the Global Uterine Fibroid Diagnostics and Therapeutics Market make the report investor’s guide.

Scope of Global Uterine Fibroid Diagnostics and Therapeutics Market: Inquire before buying


Global Uterine Fibroid Diagnostics and Therapeutics Market, by Type

• Subserosal Fibroids
• Intramural Fibroids
• Submucosal Fibroids
• Other

Global Uterine Fibroid Diagnostics and Therapeutics Market,by Diagnosis

• Medical Resonance Imaging (MRI) scanners
• Computed Tomography (CT)
• Ultrasounds
• Others

Global Uterine Fibroid Diagnostics and Therapeutics Market, by Treatment

• Uterine Fibroid Embolization
• Magnetic Resonance Guided Focused Ultrasound
• Myolysis
• Endometrial Ablation
• Hysterectomy
• Myomectomy

Global Uterine Fibroid Diagnostics and Therapeutics Market, by Region

• North America
• Europe
• Asia-Pacific
• South America
• Middle East & Africa

Global Uterine Fibroid Diagnostics and Therapeutics Market Major Players

• Roche Ltd
• Abbott Laboratories
• Becton
• Dickinson and Company and Siemens Healthcare
• AstraZeneca
• Cook Medical Inc.
• Boston Scientific Corporation
• GE Healthcare
• AbbVie Inc.
• Hologic 




Global Uterine Fibroid Diagnostics and Therapeutics Market

1. Preface
1.1. Report Scope and Market Segmentation
1.2. Research Highlights
1.3. Research Objectives

2. Assumptions and Research Methodology
2.1. Report Assumptions
2.2. Abbreviations
2.3. Research Methodology
2.3.1. Secondary Research
2.3.1.1. Secondary data
2.3.1.2. Secondary Sources
2.3.2. Primary Research
2.3.2.1. Data from Primary Sources
2.3.2.2. Breakdown of Primary Sources

3. Executive Summary: Global Uterine Fibroid Diagnostics and Therapeutics Market, by Market Value (US$ Bn) and Volume (Ton)

4. Market Overview
4.1. Introduction
4.2. Market Indicator
4.2.1. Drivers
4.2.2. Restraints
4.2.3. Opportunities
4.2.4. Challenges
4.3. Porter’s Analysis
4.4. Value Chain Analysis
4.5. Market Risk Analysis
4.6. SWOT Analysis
4.7. Industry Trends and Emerging Technologies

5. Supply Side and Demand Side Indicators

6. Global Uterine Fibroid Diagnostics and Therapeutics Market Analysis and Forecast
6.1. Global Uterine Fibroid Diagnostics and Therapeutics Market Size & Y-o-Y Growth Analysis
6.1.1. North America
6.1.2. Europe
6.1.3. Asia Pacific
6.1.4. Middle East & Africa
6.1.5. South America

7. Global Uterine Fibroid Diagnostics and Therapeutics Market Analysis and Forecast, by Type
7.1. Introduction and Definition
7.2. Key Findings
7.3. Global Uterine Fibroid Diagnostics and Therapeutics Market Value Share Analysis, by Type
7.4. Global Uterine Fibroid Diagnostics and Therapeutics Market Size (US$ Bn) Forecast, by Type
7.5. Global Uterine Fibroid Diagnostics and Therapeutics Market Analysis, by Type
7.6. Global Uterine Fibroid Diagnostics and Therapeutics Market Attractiveness Analysis, by Type

8. Global Uterine Fibroid Diagnostics and Therapeutics Market Analysis and Forecast, by Diagnosis
8.1. Introduction and Definition
8.2. Key Findings
8.3. Global Uterine Fibroid Diagnostics and Therapeutics Market Value Share Analysis, by Diagnosis
8.4. Global Uterine Fibroid Diagnostics and Therapeutics Market Size (US$ Bn) Forecast, by Diagnosis
8.5. Global Uterine Fibroid Diagnostics and Therapeutics Market Analysis, by Diagnosis
8.6. Global Uterine Fibroid Diagnostics and Therapeutics Market Attractiveness Analysis, by Diagnosis

9. Global Uterine Fibroid Diagnostics and Therapeutics Market Analysis and Forecast, by Treatment
9.1. Introduction and Definition
9.2. Key Findings
9.3. Global Uterine Fibroid Diagnostics and Therapeutics Market Value Share Analysis, by Treatment
9.4. Global Uterine Fibroid Diagnostics and Therapeutics Market Size (US$ Bn) Forecast, by Treatment
9.5. Global Uterine Fibroid Diagnostics and Therapeutics Market Analysis, by Treatment
9.6. Global Uterine Fibroid Diagnostics and Therapeutics Market Attractiveness Analysis, by Treatment

10. Global Uterine Fibroid Diagnostics and Therapeutics Market Analysis, by Region
10.1. Global Uterine Fibroid Diagnostics and Therapeutics Market Value Share Analysis, by Region
10.2. Global Uterine Fibroid Diagnostics and Therapeutics Market Size (US$ Bn) Forecast, by Region
10.3. Global Uterine Fibroid Diagnostics and Therapeutics Market Attractiveness Analysis, by Region

11. North America Uterine Fibroid Diagnostics and Therapeutics Market Analysis
11.1. Key Findings
11.2. North America Uterine Fibroid Diagnostics and Therapeutics Market Overview
11.3. North America Uterine Fibroid Diagnostics and Therapeutics Market Value Share Analysis, by Type
11.4. North America Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Type
11.4.1. Subserosal Fibroids
11.4.2. Intramural Fibroids
11.4.3. Submucosal Fibroids
11.4.4. Other
11.5. North America Uterine Fibroid Diagnostics and Therapeutics Market Value Share Analysis, by Diagnosis
11.6. North America Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Diagnosis
11.6.1. Medical Resonance Imaging (MRI) scanners
11.6.2. Computed Tomography (CT)
11.6.3. Ultrasounds
11.6.4. Others

11.7. North America Uterine Fibroid Diagnostics and Therapeutics Market Value Share Analysis, by Treatment
11.8. North America Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Treatment
11.8.1. Uterine Fibroid Embolization
11.8.2. Magnetic Resonance Guided Focused Ultrasound
11.8.3. Myolysis
11.8.4. Endometrial Ablation
11.8.5. Hysterectomy
11.8.6. Myomectomy

11.9. North America Uterine Fibroid Diagnostics and Therapeutics Market Value Share Analysis, by Country
11.10. North America Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Country
11.10.1. U.S.
11.10.2. Canada
11.11. North America Uterine Fibroid Diagnostics and Therapeutics Market Analysis, by Country
11.12. U.S. Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Type
11.12.1. Subserosal Fibroids
11.12.2. Intramural Fibroids
11.12.3. Submucosal Fibroids
11.12.4. Other

11.13. U.S. Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Diagnosis
11.13.1. Medical Resonance Imaging (MRI) scanners
11.13.2. Computed Tomography (CT)
11.13.3. Ultrasounds
11.13.4. Others

11.14. U.S. Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Treatment
11.14.1. Uterine Fibroid Embolization
11.14.2. Magnetic Resonance Guided Focused Ultrasound
11.14.3. Myolysis
11.14.4. Endometrial Ablation
11.14.5. Hysterectomy
11.14.6. Myomectomy

11.15. Canada Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Type
11.15.1. Subserosal Fibroids
11.15.2. Intramural Fibroids
11.15.3. Submucosal Fibroids
11.15.4. Other

11.16. Canada Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Diagnosis
11.16.1. Medical Resonance Imaging (MRI) scanners
11.16.2. Computed Tomography (CT)
11.16.3. Ultrasounds
11.16.4. Others

11.17. Canada Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Treatment
11.17.1. Uterine Fibroid Embolization
11.17.2. Magnetic Resonance Guided Focused Ultrasound
11.17.3. Myolysis
11.17.4. Endometrial Ablation
11.17.5. Hysterectomy
11.17.6. Myomectomy

11.18. North America Uterine Fibroid Diagnostics and Therapeutics Market Attractiveness Analysis
11.18.1. By Type
11.18.2. By Diagnosis
11.18.3. By Treatment
11.19. PEST Analysis
11.20. Key Trends
11.21. Key Development

12. Europe Uterine Fibroid Diagnostics and Therapeutics Market Analysis
12.1. Key Findings
12.2. Europe Uterine Fibroid Diagnostics and Therapeutics Market Overview
12.3. Europe Uterine Fibroid Diagnostics and Therapeutics Market Value Share Analysis, by Type
12.4. Europe Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Type
12.4.1. Subserosal Fibroids
12.4.2. Intramural Fibroids
12.4.3. Submucosal Fibroids
12.4.4. Other

12.5. Europe Uterine Fibroid Diagnostics and Therapeutics Market Value Share Analysis, by Diagnosis
12.6. Europe Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Diagnosis
12.6.1. Medical Resonance Imaging (MRI) scanners
12.6.2. Computed Tomography (CT)
12.6.3. Ultrasounds
12.6.4. Others

12.7. Europe Uterine Fibroid Diagnostics and Therapeutics Market Value Share Analysis, by Treatment
12.8. Europe Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Treatment
12.8.1. Uterine Fibroid Embolization
12.8.2. Magnetic Resonance Guided Focused Ultrasound
12.8.3. Myolysis
12.8.4. Endometrial Ablation
12.8.5. Hysterectomy
12.8.6. Myomectomy

12.9. Europe Uterine Fibroid Diagnostics and Therapeutics Market Value Share Analysis, by Country
12.10. Europe Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Country
12.10.1. Germany
12.10.2. U.K.
12.10.3. France
12.10.4. Italy
12.10.5. Spain
12.10.6. Norway
12.10.7. Rest of Europe
12.11. Europe Uterine Fibroid Diagnostics and Therapeutics Market Analysis, by Country
12.12. Germany Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Type
12.12.1. Subserosal Fibroids
12.12.2. Intramural Fibroids
12.12.3. Submucosal Fibroids
12.12.4. Other

12.13. Germany Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Diagnosis
12.13.1. Medical Resonance Imaging (MRI) scanners
12.13.2. Computed Tomography (CT)
12.13.3. Ultrasounds
12.13.4. Others
12.14. Germany Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Treatment
12.14.1. Uterine Fibroid Embolization
12.14.2. Magnetic Resonance Guided Focused Ultrasound
12.14.3. Myolysis
12.14.4. Endometrial Ablation
12.14.5. Hysterectomy
12.14.6. Myomectomy

12.15. U.K. Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Type
12.15.1. Subserosal Fibroids
12.15.2. Intramural Fibroids
12.15.3. Submucosal Fibroids
12.15.4. Other

12.16. U.K. Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Diagnosis
12.16.1. Medical Resonance Imaging (MRI) scanners
12.16.2. Computed Tomography (CT)
12.16.3. Ultrasounds
12.16.4. Others

12.17. U.K. Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Treatment
12.17.1. Uterine Fibroid Embolization
12.17.2. Magnetic Resonance Guided Focused Ultrasound
12.17.3. Myolysis
12.17.4. Endometrial Ablation
12.17.5. Hysterectomy
12.17.6. Myomectomy

12.18. France Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Type
12.18.1. Subserosal Fibroids
12.18.2. Intramural Fibroids
12.18.3. Submucosal Fibroids
12.18.4. Other

12.19. France Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Diagnosis
12.19.1. Medical Resonance Imaging (MRI) scanners
12.19.2. Computed Tomography (CT)
12.19.3. Ultrasounds
12.19.4. Others

12.20. France Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Treatment
12.20.1. Uterine Fibroid Embolization
12.20.2. Magnetic Resonance Guided Focused Ultrasound
12.20.3. Myolysis
12.20.4. Endometrial Ablation
12.20.5. Hysterectomy
12.20.6. Myomectomy

12.21. Italy Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Type
12.21.1. Subserosal Fibroids
12.21.2. Intramural Fibroids
12.21.3. Submucosal Fibroids
12.21.4. Other

12.22. Italy Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Diagnosis
12.22.1. Medical Resonance Imaging (MRI) scanners
12.22.2. Computed Tomography (CT)
12.22.3. Ultrasounds
12.22.4. Others

12.23. Italy Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Treatment
12.23.1. Uterine Fibroid Embolization
12.23.2. Magnetic Resonance Guided Focused Ultrasound
12.23.3. Myolysis
12.23.4. Endometrial Ablation
12.23.5. Hysterectomy
12.23.6. Myomectomy

12.24. Spain Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Type
12.24.1. Subserosal Fibroids
12.24.2. Intramural Fibroids
12.24.3. Submucosal Fibroids
12.24.4. Other

12.25. Spain Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Diagnosis
12.25.1. Medical Resonance Imaging (MRI) scanners
12.25.2. Computed Tomography (CT)
12.25.3. Ultrasounds
12.25.4. Others

12.26. Spain Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Treatment
12.26.1. Uterine Fibroid Embolization
12.26.2. Magnetic Resonance Guided Focused Ultrasound
12.26.3. Myolysis
12.26.4. Endometrial Ablation
12.26.5. Hysterectomy
12.26.6. Myomectomy

12.27. Norway Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Type
12.27.1. Subserosal Fibroids
12.27.2. Intramural Fibroids
12.27.3. Submucosal Fibroids
12.27.4. Other

12.28. Norway Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Diagnosis

12.28.1. Medical Resonance Imaging (MRI) scanners
12.28.2. Computed Tomography (CT)
12.28.3. Ultrasounds
12.28.4. Others

12.29. Norway Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Treatment

12.29.1. Uterine Fibroid Embolization
12.29.2. Magnetic Resonance Guided Focused Ultrasound
12.29.3. Myolysis
12.29.4. Endometrial Ablation
12.29.5. Hysterectomy
12.29.6. Myomectomy
12.30. Rest of Europe Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Type
12.30.1. Subserosal Fibroids
12.30.2. Intramural Fibroids
12.30.3. Submucosal Fibroids
12.30.4. Others

12.31. Rest of Europe Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Diagnosis
12.31.1. Medical Resonance Imaging (MRI) scanners
12.31.2. Computed Tomography (CT)
12.31.3. Ultrasounds
12.31.4. Others

12.32. Rest of Europe Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Treatment
12.32.1. Uterine Fibroid Embolization
12.32.2. Magnetic Resonance Guided Focused Ultrasound
12.32.3. Myolysis
12.32.4. Endometrial Ablation
12.32.5. Hysterectomy
12.32.6. Myomectomy

12.33. Europe Uterine Fibroid Diagnostics and Therapeutics Market Attractiveness Analysis
12.33.1. By Type
12.33.2. By Diagnosis
12.33.3. By Treatment
12.34. PEST Analysis
12.35. Key Trends
12.36. Key Development

13. Asia Pacific Uterine Fibroid Diagnostics and Therapeutics Market Analysis
13.1. Key Findings
13.2. Asia Pacific Uterine Fibroid Diagnostics and Therapeutics Market Overview
13.3. Asia Pacific Uterine Fibroid Diagnostics and Therapeutics Market Value Share Analysis, by Type
13.4. Asia Pacific Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Type
13.4.1. Subserosal Fibroids
13.4.2. Intramural Fibroids
13.4.3. Submucosal Fibroids
13.4.4. Others

13.5. Asia Pacific Uterine Fibroid Diagnostics and Therapeutics Market Value Share Analysis, by Diagnosis
13.6. Asia Pacific Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Diagnosis
13.6.1. Medical Resonance Imaging (MRI) scanners
13.6.2. Computed Tomography (CT)
13.6.3. Ultrasounds
13.6.4. Others

13.7. Asia Pacific Uterine Fibroid Diagnostics and Therapeutics Market Value Share Analysis, by Treatment
13.8. Asia Pacific Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Treatment
13.8.1. Uterine Fibroid Embolization
13.8.2. Magnetic Resonance Guided Focused Ultrasound
13.8.3. Myolysis
13.8.4. Endometrial Ablation
13.8.5. Hysterectomy
13.8.6. Myomectomy

13.9. Asia Pacific Uterine Fibroid Diagnostics and Therapeutics Market Value Share Analysis, by Country
13.10. Asia Pacific Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Country
13.10.1. China
13.10.2. India
13.10.3. Japan
13.10.4. South Korea
13.10.5. Australia
13.10.6. Malaysia
13.10.7. Indonesia
13.10.8. Vietnam
13.10.9. Rest of Asia Pacific
13.11. Asia Pacific Uterine Fibroid Diagnostics and Therapeutics Market Analysis, by Country
13.12. China Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Type
13.12.1. Subserosal Fibroids
13.12.2. Intramural Fibroids
13.12.3. Submucosal Fibroids
13.12.4. Others

13.13. China Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Diagnosis
13.13.1. Medical Resonance Imaging (MRI) scanners
13.13.2. Computed Tomography (CT)
13.13.3. Ultrasounds
13.13.4. Others

13.14. China Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Treatment
13.14.1. Uterine Fibroid Embolization
13.14.2. Magnetic Resonance Guided Focused Ultrasound
13.14.3. Myolysis
13.14.4. Endometrial Ablation
13.14.5. Hysterectomy
13.14.6. Myomectomy

13.15. India Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Type
13.15.1. Subserosal Fibroids
13.15.2. Intramural Fibroids
13.15.3. Submucosal Fibroids
13.15.4. Others

13.16. India Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Diagnosis
13.16.1. Medical Resonance Imaging (MRI) scanners
13.16.2. Computed Tomography (CT)
13.16.3. Ultrasounds
13.16.4. Others

13.17. India Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Treatment
13.17.1. Uterine Fibroid Embolization
13.17.2. Magnetic Resonance Guided Focused Ultrasound
13.17.3. Myolysis
13.17.4. Endometrial Ablation
13.17.5. Hysterectomy
13.17.6. Myomectomy

13.18. Japan Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Type
13.18.1. Subserosal Fibroids
13.18.2. Intramural Fibroids
13.18.3. Submucosal Fibroids
13.18.4. Others

13.19. Japan Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Diagnosis
13.19.1. Medical Resonance Imaging (MRI) scanners
13.19.2. Computed Tomography (CT)
13.19.3. Ultrasounds
13.19.4. Others

13.20. Japan Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Treatment
13.20.1. Uterine Fibroid Embolization
13.20.2. Magnetic Resonance Guided Focused Ultrasound
13.20.3. Myolysis
13.20.4. Endometrial Ablation
13.20.5. Hysterectomy
13.20.6. Myomectomy

13.21. Australia Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Type
13.21.1. Subserosal Fibroids
13.21.2. Intramural Fibroids
13.21.3. Submucosal Fibroids
13.21.4. Others

13.22. Australia Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Diagnosis
13.22.1. Medical Resonance Imaging (MRI) scanners
13.22.2. Computed Tomography (CT)
13.22.3. Ultrasounds
13.22.4. Others

13.23. Australia Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Treatment
13.23.1. Uterine Fibroid Embolization
13.23.2. Magnetic Resonance Guided Focused Ultrasound
13.23.3. Myolysis
13.23.4. Endometrial Ablation
13.23.5. Hysterectomy
13.23.6. Myomectomy

13.24. Malaysia Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Type
13.24.1. Subserosal Fibroids
13.24.2. Intramural Fibroids
13.24.3. Submucosal Fibroids
13.24.4. Others
13.25. Malaysia Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Diagnosis
13.25.1. Medical Resonance Imaging (MRI) scanners
13.25.2. Computed Tomography (CT)
13.25.3. Ultrasounds
13.25.4. Others

13.26. Malaysia Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Treatment
13.26.1. Uterine Fibroid Embolization
13.26.2. Magnetic Resonance Guided Focused Ultrasound
13.26.3. Myolysis
13.26.4. Endometrial Ablation
13.26.5. Hysterectomy
13.26.6. Myomectomy

13.27. South Korea Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Type
13.27.1. Subserosal Fibroids
13.27.2. Intramural Fibroids
13.27.3. Submucosal Fibroids
13.27.4. Others

13.28. South Korea Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Diagnosis
13.28.1. Medical Resonance Imaging (MRI) scanners
13.28.2. Computed Tomography (CT)
13.28.3. Ultrasounds
13.28.4. Others

13.29. South Korea Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Treatment
13.29.1. Uterine Fibroid Embolization
13.29.2. Magnetic Resonance Guided Focused Ultrasound
13.29.3. Myolysis
13.29.4. Endometrial Ablation
13.29.5. Hysterectomy
13.29.6. Myomectomy

13.30. Thailand Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Type
13.30.1. Subserosal Fibroids
13.30.2. Intramural Fibroids
13.30.3. Submucosal Fibroids
13.30.4. Others

13.31. Thailand Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Diagnosis
13.31.1. Medical Resonance Imaging (MRI) scanners
13.31.2. Computed Tomography (CT)
13.31.3. Ultrasounds
13.31.4. Others

13.32. Thailand Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Treatment
13.32.1. Uterine Fibroid Embolization
13.32.2. Magnetic Resonance Guided Focused Ultrasound
13.32.3. Myolysis
13.32.4. Endometrial Ablation
13.32.5. Hysterectomy
13.32.6. Myomectomy

13.33. Vietnam Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Type
13.33.1. Subserosal Fibroids
13.33.2. Intramural Fibroids
13.33.3. Submucosal Fibroids
13.33.4. Others

13.34. Vietnam Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Diagnosis
13.34.1. Medical Resonance Imaging (MRI) scanners
13.34.2. Computed Tomography (CT)
13.34.3. Ultrasounds
13.34.4. Others

13.35. Vietnam Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Treatment
13.35.1. Uterine Fibroid Embolization
13.35.2. Magnetic Resonance Guided Focused Ultrasound
13.35.3. Myolysis
13.35.4. Endometrial Ablation
13.35.5. Hysterectomy
13.35.6. Myomectomy

13.36. Rest of Asia Pacific Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Type
13.36.1. Subserosal Fibroids
13.36.2. Intramural Fibroids
13.36.3. Submucosal Fibroids
13.36.4. Others

13.37. Rest of Asia Pacific Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Diagnosis
13.37.1. Medical Resonance Imaging (MRI) scanners
13.37.2. Computed Tomography (CT)
13.37.3. Ultrasounds
13.37.4. Others

13.38. Rest of Asia Pacific Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Treatment
13.38.1. Uterine Fibroid Embolization
13.38.2. Magnetic Resonance Guided Focused Ultrasound
13.38.3. Myolysis
13.38.4. Endometrial Ablation
13.38.5. Hysterectomy
13.38.6. Myomectomy

13.39. Asia Pacific Uterine Fibroid Diagnostics and Therapeutics Market Attractiveness Analysis
13.39.1. By Type
13.39.2. By Diagnosis
13.39.3. By Treatment
13.40. PEST Analysis
13.41. Key Trends
13.42. Key Development

14. Middle East & Africa Uterine Fibroid Diagnostics and Therapeutics Market Analysis
14.1. Key Findings
14.2. Middle East & Africa Uterine Fibroid Diagnostics and Therapeutics Market Overview
14.3. Middle East & Africa Uterine Fibroid Diagnostics and Therapeutics Market Value Share Analysis, by Type
14.4. Middle East & Africa Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Type
14.4.1. Subserosal Fibroids
14.4.2. Intramural Fibroids
14.4.3. Submucosal Fibroids
14.4.4. Others

14.5. Middle East & Africa Uterine Fibroid Diagnostics and Therapeutics Market Value Share Analysis, by Diagnosis
14.6. Middle East & Africa Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Diagnosis
14.6.1. Medical Resonance Imaging (MRI) scanners
14.6.2. Computed Tomography (CT)
14.6.3. Ultrasounds
14.6.4. Others

14.7. Middle East & Africa Uterine Fibroid Diagnostics and Therapeutics Market Value Share Analysis, by Treatment
14.8. Middle East & Africa Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Treatment
14.8.1. Uterine Fibroid Embolization
14.8.2. Magnetic Resonance Guided Focused Ultrasound
14.8.3. Myolysis
14.8.4. Endometrial Ablation
14.8.5. Hysterectomy
14.8.6. Myomectomy

14.9. Middle East & Africa Uterine Fibroid Diagnostics and Therapeutics Market Value Share Analysis, by Country
14.10. Middle East & Africa Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Country
14.10.1. GCC
14.10.2. South Africa
14.10.3. Nigeria
14.10.4. Egypt
14.10.5. Rest of Middle East & Africa
14.11. Middle East & Africa Uterine Fibroid Diagnostics and Therapeutics Market Analysis, by Country
14.12. GCC Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Type
14.12.1. Subserosal Fibroids
14.12.2. Intramural Fibroids
14.12.3. Submucosal Fibroids
14.12.4. Others

14.13. GCC Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Diagnosis
14.13.1. Medical Resonance Imaging (MRI) scanners
14.13.2. Computed Tomography (CT)
14.13.3. Ultrasounds
14.13.4. Others

14.14. GCC Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Treatment
14.14.1. Uterine Fibroid Embolization
14.14.2. Magnetic Resonance Guided Focused Ultrasound
14.14.3. Myolysis
14.14.4. Endometrial Ablation
14.14.5. Hysterectomy
14.14.6. Myomectomy

14.15. South Africa Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Type
14.15.1. Subserosal Fibroids
14.15.2. Intramural Fibroids
14.15.3. Submucosal Fibroids
14.15.4. Others

14.16. South Africa Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Diagnosis
14.16.1. Medical Resonance Imaging (MRI) scanners
14.16.2. Computed Tomography (CT)
14.16.3. Ultrasounds
14.16.4. Others

14.17. South Africa Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Treatment
14.17.1. Uterine Fibroid Embolization
14.17.2. Magnetic Resonance Guided Focused Ultrasound
14.17.3. Myolysis
14.17.4. Endometrial Ablation
14.17.5. Hysterectomy
14.17.6. Myomectomy

14.18. Nigeria Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Type
14.18.1. Subserosal Fibroids
14.18.2. Intramural Fibroids
14.18.3. Submucosal Fibroids
14.18.4. Others

14.19. Nigeria Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Diagnosis
14.19.1. Medical Resonance Imaging (MRI) scanners
14.19.2. Computed Tomography (CT)
14.19.3. Ultrasounds
14.19.4. Others

14.20. Nigeria Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Treatment
14.20.1. Uterine Fibroid Embolization
14.20.2. Magnetic Resonance Guided Focused Ultrasound
14.20.3. Myolysis
14.20.4. Endometrial Ablation
14.20.5. Hysterectomy
14.20.6. Myomectomy

14.21. Egypt Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Type
14.21.1. Subserosal Fibroids
14.21.2. Intramural Fibroids
14.21.3. Submucosal Fibroids
14.21.4. Others

14.22. Egypt Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Diagnosis
14.22.1. Medical Resonance Imaging (MRI) scanners
14.22.2. Computed Tomography (CT)
14.22.3. Ultrasounds
14.22.4. Others

14.23. Egypt Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Treatment
14.23.1. Uterine Fibroid Embolization
14.23.2. Magnetic Resonance Guided Focused Ultrasound
14.23.3. Myolysis
14.23.4. Endometrial Ablation
14.23.5. Hysterectomy
14.23.6. Myomectomy

14.24. Rest of Middle East & Africa Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Type
14.24.1. Subserosal Fibroids
14.24.2. Intramural Fibroids
14.24.3. Submucosal Fibroids
14.24.4. Others

14.25. Rest of Middle East & Africa Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Diagnosis
14.25.1. Medical Resonance Imaging (MRI) scanners
14.25.2. Computed Tomography (CT)
14.25.3. Ultrasounds
14.25.4. Others

14.26. Rest of Middle East & Africa Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Treatment
14.26.1. Uterine Fibroid Embolization
14.26.2. Magnetic Resonance Guided Focused Ultrasound
14.26.3. Myolysis
14.26.4. Endometrial Ablation
14.26.5. Hysterectomy
14.26.6. Myomectomy

14.27. Middle East & Africa Uterine Fibroid Diagnostics and Therapeutics Market Attractiveness Analysis
14.27.1. By Type
14.27.2. By Diagnosis
14.27.3. By Treatment
14.28. PEST Analysis
14.29. Key Trends
14.30. Key Development

15. South America Uterine Fibroid Diagnostics and Therapeutics Market Analysis
15.1. Key Findings
15.2. South America Uterine Fibroid Diagnostics and Therapeutics Market Overview
15.3. South America Uterine Fibroid Diagnostics and Therapeutics Market Value Share Analysis, by Type
15.4. South America Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Type
15.4.1. Subserosal Fibroids
15.4.2. Intramural Fibroids
15.4.3. Submucosal Fibroids
15.4.4. Others

15.5. South America Uterine Fibroid Diagnostics and Therapeutics Market Value Share Analysis, by Diagnosis
15.6. South America Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Diagnosis
15.6.1. Medical Resonance Imaging (MRI) scanners
15.6.2. Computed Tomography (CT)
15.6.3. Ultrasounds
15.6.4. Others

15.7. South America Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Treatment
15.7.1. Uterine Fibroid Embolization
15.7.2. Magnetic Resonance Guided Focused Ultrasound
15.7.3. Myolysis
15.7.4. Endometrial Ablation
15.7.5. Hysterectomy
15.7.6. Myomectomy

15.8. South America Uterine Fibroid Diagnostics and Therapeutics Market Value Share Analysis, by Country
15.9. South America Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Country
15.9.1. Brazil
15.9.2. Mexico
15.9.3. Argentina
15.9.4. Rest of South America
15.10. South America Uterine Fibroid Diagnostics and Therapeutics Market Analysis, by Country
15.11. Brazil Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Type
15.11.1. Subserosal Fibroids
15.11.2. Intramural Fibroids
15.11.3. Submucosal Fibroids
15.11.4. Others

15.12. Brazil Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Diagnosis
15.12.1. Medical Resonance Imaging (MRI) scanners
15.12.2. Computed Tomography (CT)
15.12.3. Ultrasounds
15.12.4. Others

15.13. Brazil Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Treatment
15.13.1. Uterine Fibroid Embolization
15.13.2. Magnetic Resonance Guided Focused Ultrasound
15.13.3. Myolysis
15.13.4. Endometrial Ablation
15.13.5. Hysterectomy
15.13.6. Myomectomy

15.14. Mexico Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Type
15.14.1. Subserosal Fibroids
15.14.2. Intramural Fibroids
15.14.3. Submucosal Fibroids
15.14.4. Others

15.15. Mexico Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Diagnosis
15.15.1. Medical Resonance Imaging (MRI) scanners
15.15.2. Computed Tomography (CT)
15.15.3. Ultrasounds
15.15.4. Others

15.16. Mexico Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Treatment
15.16.1. Uterine Fibroid Embolization
15.16.2. Magnetic Resonance Guided Focused Ultrasound
15.16.3. Myolysis
15.16.4. Endometrial Ablation
15.16.5. Hysterectomy
15.16.6. Myomectomy

15.17. Argentina Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Type
15.17.1. Subserosal Fibroids
15.17.2. Intramural Fibroids
15.17.3. Submucosal Fibroids
15.17.4. Other
15.18. Argentina Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Diagnosis
15.18.1. Medical Resonance Imaging (MRI) scanners
15.18.2. Computed Tomography (CT)
15.18.3. Ultrasounds
15.18.4. Others

15.19. Argentina Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Treatment
15.19.1. Uterine Fibroid Embolization
15.19.2. Magnetic Resonance Guided Focused Ultrasound
15.19.3. Myolysis
15.19.4. Endometrial Ablation
15.19.5. Hysterectomy
15.19.6. Myomectomy

15.20. Rest of South America Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Type
15.20.1. Subserosal Fibroids
15.20.2. Intramural Fibroids
15.20.3. Submucosal Fibroids
15.20.4. Others
15.21. Rest of South America Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Diagnosis
15.21.1. Medical Resonance Imaging (MRI) scanners
15.21.2. Computed Tomography (CT)
15.21.3. Ultrasounds
15.21.4. Others

15.22. Rest of South America Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Treatment
15.22.1. Uterine Fibroid Embolization
15.22.2. Magnetic Resonance Guided Focused Ultrasound
15.22.3. Myolysis
15.22.4. Endometrial Ablation
15.22.5. Hysterectomy
15.22.6. Myomectomy

15.23. South America Uterine Fibroid Diagnostics and Therapeutics Market Attractiveness Analysis
15.23.1. By Type
15.23.2. By Diagnosis
15.23.3. By Treatment
15.24. PEST Analysis
15.25. Key Trends
15.26. Key Development

16. Company Profiles
16.1. Market Share Analysis, by Company
16.2. Competition Matrix
16.2.1. Competitive Benchmarking of key players by price, presence, market share, Treatments and R&D investment
16.2.2. New Product Launches and Product Enhancements
16.2.3. Market Consolidation
16.2.3.1. M&A by Regions, Investment and Treatments
16.2.3.2. M&A Key Players, Forward Integration and Backward
Integration
16.3. Company Profiles: Key Players
16.3.1. Roche Ltd

16.3.1.1. Company Overview
16.3.1.2. Financial Overview
16.3.1.3. Product Portfolio
16.3.1.4. Business Strategy
16.3.1.5. Recent Developments
16.3.1.6. Company Footprint
16.3.2. Abbott Laboratories
16.3.3. Becton
16.3.4. Dickinson and Company and Siemens Healthcare
16.3.5. AstraZeneca
16.3.6. Cook Medical Inc.
16.3.7. Boston Scientific Corporation
16.3.8. GE Healthcare
16.3.9. AbbVie Inc.
16.3.10. Hologic
  • INQUIRE BEFORE BUYING